Literature DB >> 19757136

Unusual cause of proteinuria and re-renal failure after kidney transplantation: de novo localized AL amyloidosis in renal allograft.

D J Chen1, H Jiang, H Yang, Q He, H P Wang, J H Chen.   

Abstract

Amyloidosis results from the deposition of amyloid proteins in organ and tissues. It can be systemic or localized. Localized primary amyloidosis in renal allograft is an extremely rare clinical condition. We describe here a 46-year-old man who developed proteinuria and re-renal failure 5 years after receiving deceased renal allograft and proved to be a case of isolated primary AL amyloidosis in renal allograft confirmed by clinical investigations and renal biopsy.

Entities:  

Mesh：

Year:  2009        PMID： 19757136     DOI： 10.1007/s11255-009-9635-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  9 in total

Review 1.  The relation of proteoglycans, serum amyloid P and apo E to amyloidosis current status, 2000.

Authors:  R Kisilevsky
Journal:  Amyloid       Date:  2000-03       Impact factor: 7.141

Review 2.  An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.

Authors:  V Sanchorawala; D G Wright; D C Seldin; L M Dember; K Finn; R H Falk; J Berk; K Quillen; M Skinner
Journal:  Bone Marrow Transplant       Date:  2001-10       Impact factor: 5.483

3.  Antibody-mediated resolution of light chain-associated amyloid deposits.

Authors:  R Hrncic; J Wall; D A Wolfenbarger; C L Murphy; M Schell; D T Weiss; A Solomon
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 4.  Molecular mechanisms of amyloidosis.

Authors:  Giampaolo Merlini; Vittorio Bellotti
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245

5.  Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.

Authors:  David C Seldin; Jennifer J Anderson; Vaishali Sanchorawala; Karim Malek; Daniel G Wright; Karen Quillen; Kathleen T Finn; John L Berk; Laura M Dember; Rodney H Falk; Martha Skinner
Journal:  Blood       Date:  2004-05-20       Impact factor: 22.113

6.  De novo AL amyloid in a renal allograft.

Authors:  Q C Le; T C Wood; C E Alpers
Journal:  Am J Nephrol       Date:  1998       Impact factor: 3.754

7.  Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.

Authors:  G A Tennent; L B Lovat; M B Pepys
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

8.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

9.  A primer of amyloid nomenclature.

Authors:  Per Westermark; Merrill D Benson; Joel N Buxbaum; Alan S Cohen; Blas Frangione; Shu-Ichi Ikeda; Colin L Masters; Giampaolo Merlini; Maria J Saraiva; Jean D Sipe
Journal:  Amyloid       Date:  2007-09       Impact factor: 7.141
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.